This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 May 25;381(9880):1797-8.

doi: 10.1016/S0140-6736(13)60633-9. Epub 2013 May 7.

First-in-human trial of Dz13 for nodular basal-cell carcinoma

Gabriele Grassi¹, Mario Grassi

Affiliations

PMID: 23660122
DOI: 10.1016/S0140-6736(13)60633-9

Comment

First-in-human trial of Dz13 for nodular basal-cell carcinoma

Gabriele Grassi et al. Lancet. 2013.

. 2013 May 25;381(9880):1797-8.

doi: 10.1016/S0140-6736(13)60633-9. Epub 2013 May 7.

Authors

Gabriele Grassi¹, Mario Grassi

Affiliation

¹ Department of Life Sciences, University of Trieste, Trieste 34149, Italy. ggrassi@units.it

PMID: 23660122
DOI: 10.1016/S0140-6736(13)60633-9

No abstract available

PubMed Disclaimer

Comment on

Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER).
Cho EA, Moloney FJ, Cai H, Au-Yeung A, China C, Scolyer RA, Yosufi B, Raftery MJ, Deng JZ, Morton SW, Hammond PT, Arkenau HT, Damian DL, Francis DJ, Chesterman CN, Barnetson RS, Halliday GM, Khachigian LM. Cho EA, et al. Lancet. 2013 May 25;381(9880):1835-43. doi: 10.1016/S0140-6736(12)62166-7. Epub 2013 May 7. Lancet. 2013. PMID: 23660123 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information